Characteristic | Reason for discontinuation | Overall (n = 38) | |
---|---|---|---|
Durable response (n = 27) | Toxicity (n = 11) | ||
Age | |||
Median (range) | 58 (38 – 81) | 52 (33—86) | 58 (33—86) |
Sex | |||
female | 13 (48.1%) | 3 (27.3%) | 16 (42.1%) |
male | 14 (51.9%) | 8 (72.7%) | 22 (57.9%) |
AJCC | |||
IIIB | 4 (14.8%) | 1 (9.1%) | 5 (13.2%) |
IV M1a | 1 (3.7%) | 3 (27.3%) | 4 (10.5%) |
IV M1b | 4 (14.8%) | 2 (18.2%) | 6 (15.8%) |
IV M1c | 14 (51.9%) | 5 (45.5%) | 19 (50.0%) |
IV M1d | 4 (14.8%) | 0 (0%) | 4 (10.5%) |
BRAF status | |||
Mutated | 10 (37.0%) | 5 (45.5%) | 15 (39.5%) |
Wildtype | 17 (63.0%) | 5 (45.5%) | 22 (57.9%) |
Not reported | 0 (0%) | 1 (9.1%) | 1 (2.6%) |
Regimen | |||
Ipilimumab/Nivolumab | 16 (59.3%) | 8 (72.7%) | 24 (63.2%) |
Nivolumab | 4 (14.8%) | 1 (9.1%) | 5 (13.2%) |
Pembrolizumab | 7 (25.9%) | 2 (18.2%) | 9 (23.7%) |
Duration of immunotherapy | |||
Median (range) | 24 (8.7 – 48) | 1.3 (0.69—22) | 19 (0.69—48) |
Prior surgery | 22 (81.5%) | 9 (81.8%) | 31 (81.6%) |
Prior radiotherapy | 8 (29.6%) | 2 (18.2%) | 10 (26.3%) |
Prior systemic therapy | |||
IFN | 8 (29.6%) | 1 (9.1%) | 9 (23.7%) |
Immunotherapy | 7 (25.9%) | 0 (0%) | 7 (25.9%) |
Targeted therapy | 4 (14.8%) | 3 (27.3%) | 7 (18.4%) |
Chemotherapy | 2 (7.4%) | 0 (0%) | 2 (5.3%) |
Other | 2 (7.4%) | 1 (9.1%) | 3 (7.9%) |
Toxicity ≥ grade 3 | 12 (44.4%) | 11 (100%) | 23 (60.5%) |
LDH elevateda | 3 (11.1%) | 2 (18.2%) | 5 (13.2%) |
S100 elevateda | 0 (0%) | 3 (27.3%) | 3 (7.9%) |
RECIST v1.1 groupa | |||
CR | 11 (40.7%) | 2 (18.2%) | 13 (34.2%) |
PR | 14 (51.9%) | 7 (63.6%) | 21 (55.3%) |
SD | 2 (7.4%) | 2 (18.2%) | 4 (10.5%) |